-
Coronary Interventional Surgical Control System with One-off Accessories Approved for Marketing
2023-06-01
Recently, the innovative product Coronary Interventional Surgical Control System with one-off accessories of Corindus Inc. is approved by China NMPA.
-
Shenge Bushen Capsule Approved for Marketing by China NMPA
2022-12-29
Recently, the Category 1.1 innovative traditional Chinese medicine (TCM) Shenge Bushen Capsule of Xinjiang Huachun Biological Pharmaceutical Co., Ltd was approved for marketing by China NMPA.
-
Qijiao Tiaojing Granule Approved for Marketing by China NMPA
2022-12-28
Recently, the new traditional Chinese medicine (TCM) compound preparation Qijiao Tiaojing Granule of Hunan Anbang Pharmaceutical Co., Ltd. was approved for marketing by China NMPA.
-
NMPA Holds Meeting to Promote PIC/S Accession
2023-07-29
On July 27, the Department of Drug Regulation of the NMPA holds a meeting in Kunming, Yunnan province to promote accession to the Pharmaceutical Inspection Co-operation Scheme(PIC/S).
-
Recombinant Humanized Type III Collagen Solution Approved
2023-08-16
Recently, the innovative product Recombinant Humanized Type III Collagen Solution for injection of Shanxi Jinbo Bio-pharmaceutical Co., Ltd. is approved by China NMPA.
-
Dimdazenil Capsules Approved for Marketing by China NMPA
2023-11-29
Recently, the Category 1 innovative drug Dimdazenil Capsules of Zhejiang Jingxin Pharmaceutical Co., Ltd. was approved for marketing by China NMPA. This drug is indicated for short-term treatment for insomnia patients.
